# K091601

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Contact Person: Sarah Baumann Phone: 317-521-3952   
Fax: 317-521-2324   
Email: sarah.baumann@roche.com Secondary Contact: Stephanie Greeman Phone: 317-521-2458   
Fax: 317-521-2324   
Email: stephanie.greeman@roche.com

Date Prepared: June 1, 2009

# Device Name

Proprietary name: Elecsys Anti-CCP CalCheck

Common name: Anti-CCP CalCheck

Classification name: Single (specified) analyte controls (assayed and unassayed)

# Predicate device

The Elecsys Anti-CCP CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys C-Peptide CalCheck (K040157).

# Device Description

# 510(k) Summary, Continued

# Intended use

For use in the verification of the calibration established by the Elecsys Anti-CCP reagent on the indicated Elecsys and cobas e immunoassay analyzers.

The table below compares Elecsys Anti-CCP CalCheck with the predicate device, Elecsys C-Peptide Calcheck (K040157).

Comparison Table   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys C- Peptide CalCheck(K040157)</td><td rowspan=1 colspan=1>Elecsys Anti-CCP CalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by theElecsys C-Peptide reagent on theElecsys and cobas e immunoassayanalyzers.</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by the ElecsysAnti-CCP reagent on the indicatedElecsys and cobas e immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute with exactly 1.0 mLdistilled or deionized water andallow to stand closed for 15minutes, then mix gently byinversion.</td><td rowspan=1 colspan=1>Same.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 28°C until expirationdateReconstituted:2025°C : 4 hrs</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum</td><td rowspan=1 colspan=1>Human serum</td></tr></table>

# Performance Characteristics

The Elecsys Anti-CCP CalCheck was evaluated for value assignment and stability.

Roche Diagnostics Corporation   
c/o Sarah Baumann   
9115 Hague Road   
Box 50140   
Indianapolis, IN 46250-0457

# SEP 2 5 2009

Re: k091601 Trade/Device Name: Elecsys Anti-CCP CalCheck . Regulation Number: 21 CFR $\$ 862.1660$ Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I, reserved Product Code: JJX Dated: September 8, 2009 Received: September 14, 2009

Dear Sarah Baumann:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class ⅢI (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In adition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of InVitroDagostic DeviceEvaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postniarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

4C.1

Courtney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known):

Device Name: Elecsys Anti-CCP CalCheck

Indication For Use:

For us  he ection  he clrattablishe by he ElecyAnt-C on the indicated Elecsys and cobas e immunoassay analyzers.

# Concurrence  CDRH, Officf In VitroDiagnostic Device Evaluation and Safety OIVD)

![](images/2e1370a8f3b2c780e1f8eaf42cb0248f557accecef0cdd905cc9fa21d9d052cb.jpg)

Division SigntOff   
Office of In Vitro Diagnostic Device   
Evaluation and Safety